GLPwatch
Tirzepatide for the Treatment of Cannabis Use Disorder
NCT07265752 · Not yet recruiting
Last updated 2026-05-28This clinical trial is testing whether the medication tirzepatide can help reduce cravings for cannabis in adults with cannabis use disorder.
Status Not yet recruiting Approved but enrollment has not started.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 6 people Planned (estimated).
Who can join Ages 18+ · all sexes
Timeline Started 2026-07 · est. completion 2028-06
What this study is testing ClinicalTrials.gov NCT07265752 ↗
Description as written by the study sponsor.
This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder.
Treatments tested
- Tirzepatide Drug
2.5mg subcutaneous injection once
- Placebo Drug
Saline placebo subcutaneous injection once
| Main thing measured | Cue-Induced Craving |
|---|---|
| Sponsor | Brigham and Women's Hospital |
| Conditions studied | Cannabis Use Disorder |
| GLP-1 drugs | tirzepatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07265752 ↗